>Globaler Markt für molekulare Point-of-Care-Tests (mit NAAT), nach Produkt (Instrumente, Verbrauchsmaterialien und Reagenzien), Indikation (Tests auf Atemwegsinfektionen, Tests auf sexuell übertragbare Infektionen (STI) , Tests auf Magen-Darm-Infektionen und andere), Endbenutzer (Labore, Krankenhäuser, Kliniken, ambulante Zentren, häusliche Pflege, Einrichtungen für betreutes Wohnen und andere), Testmethode (verschreibungspflichtige Tests und OTC-Tests), Vertriebskanal (Krankenhausapotheke, Einzelhandelsapotheke und Online-Apotheke) – Branchentrends und Prognose bis 2028.
Molekulare Point-of-Care-Tests (mit NAAT) Marktanalyse und Einblicke
Der globale Markt für molekulare Point-of-Care-Tests (mit NAAT) wird voraussichtlich wachsen, da sich Gesundheitseinrichtungen und -infrastrukturen verbessern und End-of-Care-Tests in Krankenhäusern, Laboren und Kliniken eingeführt werden, was das Wachstum des Marktes vorantreiben kann. Zu den anderen Faktoren, die die Entwicklung des Marktes für molekulare Point-of-Care-Tests (mit NAAT) vorantreiben dürften, gehört die steigende Prävalenz von Infektionskrankheiten.
Andere Faktoren, wie der Mangel an qualifizierten Fachkräften und die hohen Kosten für maßgeschneiderte molekulare Point-of-Care-Tests (mit NAAT), hemmen das Wachstum des globalen Marktes für molekulare End-of-Care-Tests (mit NAAT). Andererseits bieten die gestiegenen Gesundheitsausgaben und Schwellenländer mit entwickelten Krankenhäusern eine Chance für das Wachstum des globalen Marktes für molekulare Point-of-Care-Tests (mit NAAT).
Data Bridge Market Research analysiert, dass der weltweite Markt für molekulare Point-of-Care-Tests (mittels NAAT) von 2021 bis 2028 mit einer durchschnittlichen jährlichen Wachstumsrate von 10,8 % wachsen wird.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2021 bis 2028 |
|
Basisjahr |
2020 |
|
Historische Jahre |
2019 |
|
Quantitative Einheiten |
Umsatz in Millionen USD, Preise in USD |
|
Abgedeckte Segmente |
Nach Produkt (Instrumente, Verbrauchsmaterialien und Reagenzien), Indikation (Tests auf Atemwegsinfektionen, Tests auf sexuell übertragbare Infektionen (STI), Tests auf Infektionen des Magen-Darm-Trakts und andere), Endbenutzer (Labore, Krankenhäuser, Kliniken, ambulante Zentren, häusliche Pflege, Einrichtungen für betreutes Wohnen und andere), Testmethode (verschreibungspflichtige Tests und OTC-Tests), Vertriebskanal (Krankenhausapotheke, Einzelhandelsapotheke und Online-Apotheke) |
|
Abgedeckte Länder |
Nordamerika (USA, Kanada), Europa (Großbritannien, Deutschland, Frankreich, Spanien, Italien, Rest von Europa), Südasien (Pakistan, Bangladesch, Indien, Rest von Südasien), Südostasien (Singapur, Malaysia, Vietnam, Indonesien, Thailand, Philippinen, Rest von Südostasien), Naher Osten (Saudi-Arabien, Vereinigte Arabische Emirate, Ägypten, Israel und Rest des Nahen Ostens) und Afrika (Südafrika, Kenia, Nigeria und Rest von Afrika) |
|
Abgedeckte Marktteilnehmer |
SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific Inc, binx Health, Inc., Lucira, Meridian Bioscience, Quantumdx Group Ltd., BD, Biomérieux Sa, Qiagen, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories, Inc., Sekisui Diagnostic, Randox Laboratories Ltd., GenMark Diagnostics, Seegene Inc. Grifols SA, Wondfo, Oxford Nanopore Diagnostic, PerkinElmer Inc. und Co-Diagnostic, |
Marktdefinition des globalen Marktes für molekulare Point-of-Care-Tests (unter Verwendung von NAAT)
POCT ist ein Test, der in der Nähe des Patienten durchgeführt werden kann und bei dem sofort eine medizinische Entscheidung einschließlich der Ergebnisse und einer Überwachung getroffen werden kann. POCT-Geräte, die jetzt in den klinischen Einsatz kommen, basieren auf Nukleinsäureamplifikationstechnologien (NAAT), die hier als Geräte der zweiten Generation definiert werden. Diese Plattformen weisen im Allgemeinen eine verbesserte Sensitivität von 60 bis 90 % im Vergleich zu POCTs der ersten Generation auf und erfordern tragbare Geräte mit einer Stellfläche von etwa 30 x 30 cm. Diese Geräte werden im Wesentlichen zum molekularen Nachweis verschiedener Krankheiten wie HIV , HPV und Atemwegserkrankungen mittels NAAT-Technologie verwendet. NAAT ist eine Nukleinsäureamplifikationstechnik, die die Identifizierung pathogener Organismen durch Nachweis ihrer DNA oder RNA ermöglicht.
Im Zuge der weltweiten Pandemie wurden im Zuge einer Synergie aus der Sensibilität von NAATs und der Benutzerfreundlichkeit von POCT-Tests miniaturisierte NAAT-basierte POCT-Geräte und -Tests für ein schnelleres Screening und eine schnellere Diagnose von COVID-19 entwickelt, was ebenfalls das Marktwachstum vorantrieb.
Globale Marktdynamik für molekulare Point-of-Care-Tests (mit NAAT)
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:
Treiber
- Zunahme der Prävalenz chronischer Krankheiten
Es ist allgemein bekannt, dass die Verschlechterung der Gesundheit mit zunehmendem Alter beginnt. Da die Zahl chronischer Krankheiten mit der Zeit zunimmt, nehmen auch die mit den Krankheitsraten verbundenen Faktoren zu. Die hohe Zahl fettleibiger/übergewichtiger Menschen hat auch die Prävalenz chronischer Krankheiten in verschiedenen Regionen der Welt erhöht. Der Anstieg der Zahl chronischer Krankheiten wie HPV, STI und TB hat dazu geführt, dass sich die Menschen für NAAT-basierte Point-of-Care-Tests und -Produkte zum Testen entscheiden. Dies wird daher das Wachstum des globalen Marktes für molekulare Point-of-Care-Tests (mit NAAT) in den kommenden Jahren vorantreiben.
- Verbesserung der Diagnoserate
Mit der Zunahme erfolgreicher Diagnosen chronischer Krankheiten wie Krebs, Anämie, Typ-2-Diabetes und anderer Krankheiten bieten die Fachkräfte für verbesserte Gesundheitsfürsorge regelmäßige Schulungen für das Fachpersonal zur Durchführung von Tests an, um die Diagnoserate in der Region zu verbessern. Mit der Zunahme der Krankheitslast steigt auch die Diagnoserate. Mit den Fortschritten in der Diagnose steigt auch die Rate der Menschen, die die Diagnose erhalten.
- Steigende Vorliebe für Tests in der Heimpflege
Durch die häusliche Gesundheitsfürsorge sind klinische Informationen am richtigen Ort und zur richtigen Zeit verfügbar. Sie trägt auch dazu bei, Fehler zu reduzieren und die Sicherheit bei garantierter Qualität zu erhöhen. Sie hilft auch älteren Menschen im Falle eines medizinischen Notfalls. Im Gesundheitswesen wurden viele strategische Änderungen vorgenommen, um die Vorteile von Point-of-Care-Tests zu nutzen. Laut der Weltgesundheitsorganisation (WHO) wird die Zahl der Menschen im Alter von 65 Jahren und älter voraussichtlich von geschätzten 524 Millionen im Jahr 2010 auf etwa 1,5 Milliarden im Jahr 2050 steigen, wobei die Industrieländer den größten Anteil an diesem Anstieg haben werden.
Gelegenheiten
- STRATEGISCHE INITIATIVEN DER MARKTTEILNEHMER
Eine weltweite Zunahme chronischer und nicht chronischer Krankheiten sowie die Zunahme der geriatrischen Bevölkerung in Afrika und Asien haben zu einer stärkeren Nachfrage nach der Entwicklung neuer Kits und Lösungen für molekulare Point-of-Care-Tests mit besserer Wirksamkeit und geringerem Zeitaufwand geführt. Um Diagnose und Screening in dieser Region anbieten zu können, gehen die Marktteilnehmer Partnerschaften und Vereinbarungen ein, um der Weltbevölkerung mithilfe von Kits und Instrumenten eine qualitativ hochwertige Versorgung zu bieten.
- Anstieg der Gesundheitsausgaben
Steigende Gesundheitsausgaben und -infrastruktur können Patienten dabei helfen, problemlos eine moderne Behandlung zu erhalten, die ihnen bessere Diagnosen, Verfahren und Behandlungen für eine schnelle Genesung ermöglicht. Point-of-Care-Testgeräte sind hilfreich bei der Erkennung verschiedener Krankheiten und unterstützen Behandlungspläne mithilfe von POC-Software und -Lösungen. Die Gesundheitsausgaben umfassen Eigenzahlungen (Personen, die für ihre Behandlung bezahlen), staatliche Ausgaben und Quellen wie Krankenversicherungen und Aktivitäten von Nichtregierungsorganisationen.
Einschränkungen/Herausforderungen
- HOHE PRODUKTKOSTEN
Die Entwicklung von Point-of-Care-Testprodukten erfordert erhebliche Kosten. Da das Konzept festgelegt werden muss, müssen die Materialien beschafft werden und es ist wichtig, Vorlaufzeiten zu berücksichtigen. Darüber hinaus ist der Prozess zeitaufwändig, da das Gerätedesign ausreichend Zeit benötigt, um vollständig auszureifen, bevor es auf den Markt gebracht werden kann.
- Fehlende Übereinstimmung mit den Testergebnissen aus Laboren
Im Vergleich zu den Ergebnissen von Laborteststandards unterscheiden sich die NAAT-Testergebnisse. Labortests sind fortschrittlicher, folgen dem Prozess, Protokoll und der Wissenschaft für Labortests und sind vollständig in die Technologie integriert, die zur genauen Analyse, Validierung und Dokumentation von Effekten erforderlich ist. POCT/NAAT ist jedoch zweifellos mit einem Mangel an präzisen Ergebnissen verbunden. Molekulares POCT kann die Standardisierung nicht abschließen, und andere kritische Kriterien können die Standardisierung und verschiedene wesentliche Standards nicht erreichen. Dies stellt eine erhebliche Herausforderung für den globalen Markt für molekulare Point-of-Care-Tests dar. Die PoC-Tests können manchmal fehlerhafte Ergebnisse liefern und leiden unter Variabilität der Testergebnisse.
Auswirkungen von COVID-19 auf den globalen Markt für molekulare Point-of-Care-Tests (mit NAAT)
COVID-19 hatte große Auswirkungen auf den Markt für molekulare Point-of-Care-Tests (mit NAAT). COVID-19 hat den Preis und die Nachfrage nach Produkten für molekulare Point-of-Care-Tests (mit NAAT) aufgrund des fortschreitenden Online-Verkaufs und des technologischen Fortschritts bei den Produkten positiv beeinflusst. Der Ausbruch der COVID-19-Pandemie hatte aufgrund des hohen Bedarfs an molekularen Point-of-Care-Tests (mit NAAT), insbesondere in verschiedenen Krankenhäusern, einen positiven Einfluss auf das Marktwachstum. In den meisten Krankenhäusern wird derzeit der COVID-19-Behandlung Priorität eingeräumt, da der Anstieg der COVID-19-Fälle weiterhin anhält, was auch den Einsatz molekularer Point-of-Care-Tests (mit NAAT) erhöht. Darüber hinaus haben viele internationale Regierungen und Gesundheitsorganisationen die Bereitstellung dieser Produkte aufgrund ihrer hohen Priorität in kritischen Fällen unterstützt.
Jüngste Entwicklungen
- Im November 2021 gab F.Hoffmann-La Roche Ltd bekannt, dass Roche im Dow Jones Sustainability Index zum dreizehnten Mal in Folge zu den drei nachhaltigsten Gesundheitsunternehmen zählt. Dies steigerte die Geschäftskapazität und die Geschäftsexpansion im Prognosezeitraum.
- Im Oktober 2021 erhielt die Thermo Fisher Scientific Corporation die FDA-Zulassung für den TaqMan COVID-19-Test SARS-COV Molekulartest. Dies erweiterte das Produktportfolio des Unternehmens und trug im Prognosezeitraum zum Umsatz des Unternehmens bei.
Globaler Markt für molekulare Point-of-Care-Tests (mit NAAT)
Der globale Markt für molekulare Point-of-Care-Tests (unter Verwendung von NAAT) ist in fünf wichtige Segmente unterteilt, basierend auf Produkt, Indikation, Endbenutzer, Testmethode und Vertriebskanal. Das Wachstum dieser Segmente wird dazu beitragen, Marktwachstumssegmente in den Branchen zu analysieren und den Benutzern einen wertvollen Marktüberblick und Markteinblicke zu bieten, die ihnen dabei helfen, strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.
Produkt
- Instrumente
- Verbrauchsmaterialien und Reagenzien
Basierend auf dem Produkt ist der globale Markt für molekulare Point-of-Care-Tests (mit NAAT) in Instrumente, Verbrauchsmaterialien und Reagenzien segmentiert.
Anzeige
- Tests auf sexuell übertragbare Infektionen (STI)
- Tests auf Atemwegsinfektionen
- Tests auf Infektionen des Gastrointestinaltrakts
- Sonstiges
Basierend auf der Indikation ist der globale Markt für molekulare Point-of-Care-Tests (mit NAAT) in Tests auf sexuell übertragbare Infektionen (STI), Tests auf Infektionen der Atemwege, Tests auf Infektionen des Gastrointestinaltrakts und andere unterteilt.
Endbenutzer
- Laboratorien
- Krankenhäuser
- Kliniken
- Ambulante Zentren
- Heimpflege
- Betreutes Wohnen
- Sonstiges
Basierend auf dem Endbenutzer ist der globale Markt für molekulare Point-of-Care-Tests (mit NAAT) in Labore, Krankenhäuser, Kliniken, ambulante Zentren, häusliche Pflege, Einrichtungen für betreutes Wohnen und andere unterteilt.
Testmodus
- Verschreibungspflichtige Tests
- OTC-Tests
Basierend auf der Testmethode ist der globale Markt für molekulare Point-of-Care-Tests (mit NAAT) in verschreibungspflichtige Tests und OTC-Tests unterteilt .
Vertriebskanal
- Krankenhausapotheke
- Einzelhandelsapotheke
- Online-Apotheke
Basierend auf dem Vertriebskanal ist der globale Markt für molekulare Point-of-Care-Tests (mit NAAT) in Krankenhausapotheken, Einzelhandelsapotheken und Online-Apotheken segmentiert.
Globale Marktanalyse für molekulare Point-of-Care-Tests (mit NAAT) – regionale Erkenntnisse
Der globale Markt für molekulare Point-of-Care-Tests (mit NAAT) ist basierend auf Produkt, Indikation, Endbenutzer, Testmodus und Vertriebskanal in fünf wichtige Segmente unterteilt.
Der globale Markt für molekulare Point-of-Care-Tests (mit NAAT) ist in die Länder Nordamerika (USA, Kanada), Europa (Großbritannien, Deutschland, Frankreich, Spanien, Italien, Rest von Europa), Südasien (Pakistan, Bangladesch, Indien, Rest von Südasien), Südostasien (Singapur, Malaysia, Vietnam, Indonesien, Thailand, Philippinen, Rest von Südostasien), Naher Osten (Saudi-Arabien, Vereinigte Arabische Emirate, Ägypten, Israel und Rest des Nahen Ostens) und Afrika (Südafrika, Kenia, Nigeria und Rest von Afrika) unterteilt.
Nordamerika dominiert den globalen Markt für molekulare Point-of-Care-Tests (unter Verwendung von NAAT) mit einer durchschnittlichen jährlichen Wachstumsrate von rund 12,1 % in Bezug auf Marktanteil und Marktumsatz. Diese Dominanz wird im Prognosezeitraum weiter ausgebaut. Dies ist auf die steigende Verbreitung von Infektions- und chronischen Krankheiten und die Einführung von Point-of-Care-Tests in Krankenhäusern zurückzuführen.
Wettbewerbsumfeld und globale Analyse der Marktanteile von Molekularen Point-of-Care-Tests (mit NAAT)
Das Wettbewerbsumfeld auf dem globalen Markt für molekulare Point-of-Care-Tests (mit NAAT) liefert Einzelheiten zum Wettbewerber. Die enthaltenen Komponenten sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -einrichtungen, Stärken und Schwächen des Unternehmens, Produkteinführung, behördliche Richtlinien, Markenanalyse, Produktzulassungen, Produktnutzlast, Anwendungsdominanz, Technologie-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens auf den globalen Markt für molekulare Point-of-Care-Tests (mit NAAT).
Danaher ist der dominierende Marktteilnehmer. Einige der anderen großen Akteure auf dem globalen Markt für molekulare Point-of-Care-Tests (mit NAAT) sind unter anderem SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc, binx Health, Inc., Lucira, Meridian Bioscience, Quantumdx Group Ltd., BD, Biomérieux Sa, Qiagen, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories, Inc., Sekisui Diagnostic, Randox Laboratories Ltd., GenMark Diagnostics, Seegene Inc. Grifols SA, Wondfo, Oxford Nanopore Diagnostic, PerkinElmer Inc. und Co-Diagnostic.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES
4.3.1 CEPHEID
4.3.2 THERMO FISHER SCIENTIFIC INC.
4.3.3 HOLOGIC, INC.
4.3.4 BD
4.3.5 F. HOFFMANN-LA ROCHE LTD
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY
4.5 DISTRIBUTORS
4.5.1 NORTH AMERICA
4.5.2 EUROPE
4.5.3 SOUTH ASIA
4.5.4 SOUTH EAST ASIA
4.5.5 MIDDLE EAST
4.5.6 AFRICA
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING HEALTHCARE EXPENDITURE
6.3.3 PANDEMIC OUTBREAK OF COVID-19
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.4 CHALLENGES
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
6.4.2 LACK OF ACCESSIBILITY
7 IMPACT OF COVID-19 ON THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19
7.5 CONCLUSION:
8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & REAGENTS
8.3 INSTRUMENTS
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)
9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS TESTING
9.2.1 COVID-19
9.2.2 FLU B
9.2.3 FLU A
9.2.4 RSV
9.2.5 TUBERCULOSIS
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)
9.2.7 OTHERS
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING
9.3.1 TV
9.3.2 CT
9.3.3 NG
9.3.4 HPV
9.3.5 HSV
9.3.6 MG
9.3.7 UU
9.3.8 MH
9.3.9 OTHERS
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING
9.4.1 GROUP B STREPTOCOCCUS
9.4.2 SHIGA TOXIN
9.4.3 H. PYLORI
9.5 OTHERS
10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER
10.1 OVERVIEW
10.2 LABORATORIES
10.2.1 POLYMERASE CHAIN REACTION
10.2.2 ISOTHERMAL AMPLIFICATION
10.3 HOSPITAL
10.3.1 POLYMERASE CHAIN REACTION
10.3.2 ISOTHERMAL AMPLIFICATION
10.4 CLINICS
10.4.1 POLYMERASE CHAIN REACTION
10.4.2 ISOTHERMAL AMPLIFICATION
10.5 AMBULATORY CENTER
10.5.1 POLYMERASE CHAIN REACTION
10.5.2 ISOTHERMAL AMPLIFICATION
10.6 HOMECARE
10.6.1 POLYMERASE CHAIN REACTION
10.6.2 ISOTHERMAL AMPLIFICATION
10.7 ASSISTED LIVING FACILITIES
10.7.1 POLYMERASE CHAIN REACTION
10.7.2 ISOTHERMAL AMPLIFICATION
10.8 OTHERS
11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING
11.1 OVERVIEW
11.2 PRESCRIPTION-BASED TESTING
11.3 OTC TESTING
12 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 RETAIL PHARMACY
12.4 ONLINE PHARMACY
13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.3 EUROPE
13.3.1 U.K.
13.3.2 GERMANY
13.3.3 ITALY
13.3.4 FRANCE
13.3.5 SPAIN
13.3.6 REST OF EUROPE
13.4 SOUTH ASIA
13.4.1 INDIA
13.4.2 PAKISTAN
13.4.3 BANGLADESH
13.4.4 REST OF SOUTH ASIA
13.5 SOUTH EAST ASIA
13.5.1 SINGAPORE
13.5.2 VIETNAM
13.5.3 THAILAND
13.5.4 MALAYSIA
13.5.5 INDONESIA
13.5.6 PHILIPPINES
13.5.7 REST OF SOUTH EAST ASIA
13.6 MIDDLE EAST
13.6.1 SAUDI ARABIA
13.6.2 U.A.E
13.6.3 ISRAEL
13.6.4 EGYPT
13.6.5 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 SOUTH AFRICA
13.7.2 KENYA
13.7.3 NIGERIA
13.7.4 REST OF AFRICA
14 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: SOUTH ASIA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 DANAHER
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 F.HOFFMANN-LA-ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 ABBOTT
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 BINX HEALTH, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BIOMERIEUX SA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 CO-DIAGNOSTICS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 GENMARK DIAGNOSTICS, INC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 GRIFOLS, S.A.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 LUCIRA HEALTH INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 MERIDIAN BIOSCIENCE
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 QUANTUMDX GROUP LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 QUIDEL CORPORATION
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 SD BIOSENSOR, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 WONDFO
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)
TABLE 7 DISTRIBUTORS ACROSS NORTH AMERICA
TABLE 8 DISTRIBUTORS ACROSS EUROPE
TABLE 9 DISTRIBUTORS ACROSS SOUTH ASIA
TABLE 10 DISTRIBUTORS ACROSS SOUTH EAST ASIA
TABLE 11 DISTRIBUTORS ACROSS MIDDLE EAST
TABLE 12 DISTRIBUTORS ACROSS AFRICA
TABLE 13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 14 GLOBAL CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 GLOBAL INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 GLOBAL INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 17 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 18 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 20 GLOBAL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 GLOBAL SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 22 GLOBAL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 24 GLOBAL OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 26 GLOBAL LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 GLOBAL LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 GLOBAL HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 GLOBAL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 GLOBAL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 GLOBAL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 GLOBAL AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 GLOBAL AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 34 GLOBAL HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 GLOBAL HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 36 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 38 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 40 GLOBAL PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 41 GLOBAL OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 GLOBAL HOSPITAL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 GLOBAL RETAIL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 GLOBAL ONLINE PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 U.S. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 65 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 66 U.S. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 67 U.S. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 68 U.S. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 69 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 U.S. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 71 U.S. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 72 U.S. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 U.S. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 U.S. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 U.S. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 76 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 77 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 78 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 79 CANADA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 80 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 81 CANADA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 82 CANADA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 83 CANADA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 84 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 CANADA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 CANADA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 87 CANADA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 88 CANADA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 89 CANADA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 90 CANADA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 91 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 92 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 94 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 95 EUROPE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 96 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 97 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 98 EUROPE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 99 EUROPE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 100 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 101 EUROPE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 102 EUROPE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 103 EUROPE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 104 EUROPE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 105 EUROPE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 106 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 107 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 108 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 109 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 110 U.K. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 111 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 112 U.K. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 113 U.K. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 114 U.K. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 115 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 116 U.K. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 117 U.K. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 118 U.K. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 119 U.K. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 120 U.K. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 121 U.K. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 122 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 123 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 124 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 125 GERMANY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 127 GERMANY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 128 GERMANY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 129 GERMANY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 130 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 131 GERMANY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 132 GERMANY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 133 GERMANY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 134 GERMANY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 135 GERMANY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 136 GERMANY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 137 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 138 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 139 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 140 ITALY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 141 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 142 ITALY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 143 ITALY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 144 ITALY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 145 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 146 ITALY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 147 ITALY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 148 ITALY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 149 ITALY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 150 ITALY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 151 ITALY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 152 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 153 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 155 FRANCE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 156 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 157 FRANCE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 158 FRANCE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 159 FRANCE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 160 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 161 FRANCE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 162 FRANCE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 163 FRANCE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 164 FRANCE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 165 FRANCE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 166 FRANCE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 167 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 168 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 170 SPAIN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 171 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 172 SPAIN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 173 SPAIN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 174 SPAIN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 175 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 176 SPAIN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 177 SPAIN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 178 SPAIN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 179 SPAIN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 180 SPAIN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 181 SPAIN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 182 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 183 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 REST OF EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 185 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 186 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 187 SOUTH ASIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 188 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 189 SOUTH ASIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 190 SOUTH ASIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 191 SOUTH ASIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 192 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 193 SOUTH ASIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 194 SOUTH ASIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 195 SOUTH ASIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 196 SOUTH ASIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 197 SOUTH ASIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 198 SOUTH ASIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 199 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 200 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 201 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 202 INDIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 203 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 204 INDIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 205 INDIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 206 INDIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 207 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 208 INDIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 209 INDIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 210 INDIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 211 INDIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 212 INDIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 213 INDIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 214 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 215 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 216 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 217 PAKISTAN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 218 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 219 PAKISTAN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 220 PAKISTAN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 221 PAKISTAN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 222 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 223 PAKISTAN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 224 PAKISTAN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 225 PAKISTAN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 226 PAKISTAN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 227 PAKISTAN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 228 PAKISTAN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 229 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 230 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 231 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 232 BANGLADESH INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 233 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 234 BANGLADESH RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 235 BANGLADESH SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 236 BANGLADESH GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 237 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 238 BANGLADESH LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 239 BANGLADESH HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 240 BANGLADESH CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 241 BANGLADESH AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 242 BANGLADESH HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 243 BANGLADESH ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 244 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 245 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 246 REST OF SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 247 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 248 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 249 SOUTH EAST ASIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 250 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 251 SOUTH EAST ASIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 252 SOUTH EAST ASIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 253 SOUTH EAST ASIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 254 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 255 SOUTH EAST ASIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 256 SOUTH EAST ASIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 257 SOUTH EAST ASIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 258 SOUTH EAST ASIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 259 SOUTH EAST ASIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 260 SOUTH EAST ASIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 261 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 262 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 263 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 264 SINGAPORE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 265 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 266 SINGAPORE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 267 SINGAPORE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 268 SINGAPORE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 269 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 270 SINGAPORE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 271 SINGAPORE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 272 SINGAPORE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 273 SINGAPORE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 274 SINGAPORE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 275 SINGAPORE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 276 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 277 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 278 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 279 VIETNAM INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 280 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 281 VIETNAM RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 282 VIETNAM SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 283 VIETNAM GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 284 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 285 VIETNAM LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 286 VIETNAM HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 287 VIETNAM CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 288 VIETNAM AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 289 VIETNAM HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 290 VIETNAM ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 291 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 292 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 293 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 294 THAILAND INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 295 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 296 THAILAND RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 297 THAILAND SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 298 THAILAND GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 299 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 300 THAILAND LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 301 THAILAND HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 302 THAILAND CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 303 THAILAND AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 304 THAILAND HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 305 THAILAND ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 306 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 307 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 308 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 309 MALAYSIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 310 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 311 MALAYSIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 312 MALAYSIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 313 MALAYSIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 314 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 315 MALAYSIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 316 MALAYSIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 317 MALAYSIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 318 MALAYSIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 319 MALAYSIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 320 MALAYSIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 321 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 322 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 323 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 324 INDONESIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 325 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 326 INDONESIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 327 INDONESIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 328 INDONESIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 329 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 330 INDONESIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 331 INDONESIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 332 INDONESIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 333 INDONESIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 334 INDONESIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 335 INDONESIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 336 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 337 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 338 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 339 PHILIPPINES INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 340 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 341 PHILIPPINES RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 342 PHILIPPINES SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 343 PHILIPPINES GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 344 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 345 PHILIPPINES LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 346 PHILIPPINES HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 347 PHILIPPINES CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 348 PHILIPPINES AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 349 PHILIPPINES HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 350 PHILIPPINES ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 351 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 352 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 353 REST OF SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 354 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 355 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 356 MIDDLE EAST INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 357 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 358 MIDDLE EAST RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 359 MIDDLE EAST SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 360 MIDDLE EAST GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 361 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 362 MIDDLE EAST LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 363 MIDDLE EAST HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 364 MIDDLE EAST CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 365 MIDDLE EAST AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 366 MIDDLE EAST HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 367 MIDDLE EAST ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 368 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 369 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 370 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 371 SAUDI ARABIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 372 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 373 SAUDI ARABIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 374 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 375 SAUDI ARABIAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 376 SAUDI ARABIAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 377 SAUDI ARABIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 378 SAUDI ARABIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 379 SAUDI ARABIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 380 SAUDI ARABIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 381 SAUDI ARABIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 382 SAUDI ARABIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 383 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 384 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 385 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 386 U.A.E INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 387 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 388 U.A.E RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 389 U.A.E SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 390 U.A.E GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 391 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 392 U.A.E LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 393 U.A.E HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 394 U.A.E CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 395 U.A.E AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 396 U.A.E HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 397 U.A.E ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 398 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 399 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 400 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 401 ISRAEL INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 402 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 403 ISRAEL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 404 ISRAEL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 405 ISRAEL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 406 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 407 ISRAEL LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 408 ISRAEL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 409 ISRAEL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 410 ISRAEL AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 411 ISRAEL HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 412 ISRAEL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 413 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 414 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 415 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 416 EGYPT INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 417 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 418 EGYPT RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 419 EGYPT SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 420 EGYPT GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 421 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 422 EGYPT LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 423 EGYPT HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 424 EGYPT CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 425 EGYPT AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 426 EGYPT HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 427 EGYPT ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 428 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 429 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 430 REST OF MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 431 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 432 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 433 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 434 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 435 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 436 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 437 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 438 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 439 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 440 AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 441 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 442 AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 443 AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 444 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 445 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 446 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 447 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 448 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 449 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 450 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 451 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 452 SOUTH AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 453 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 454 SOUTH AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 455 SOUTH AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 456 SOUTH AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 457 SOUTH AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 458 SOUTH AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 459 SOUTH AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 460 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 461 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 462 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 463 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 464 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 465 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 466 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 467 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 468 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 469 KENYA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 470 KENYA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 471 KENYA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 472 KENYA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 473 KENYA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 474 KENYA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 475 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 476 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 477 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 478 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 479 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 480 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 481 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 482 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 483 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 484 NIGERIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 485 NIGERIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 486 NIGERIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 487 NIGERIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 488 NIGERIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 489 NIGERIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 490 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 491 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 492 REST OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 2 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID
FIGURE 11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS-SEEKING RATE ARE EXPECTED TO DRIVE THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD
FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE MOLECULAR POINT OF CARE TESTING (USING NAAT) MANUFACTURERS IN THE FORECAST PERIOD
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
FIGURE 17 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016
FIGURE 18 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020
FIGURE 19 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 20 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 21 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 22 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020
FIGURE 23 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 24 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 25 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 26 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020
FIGURE 27 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 28 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)
FIGURE 29 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020
FIGURE 31 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)
FIGURE 32 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)
FIGURE 33 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 34 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 36 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 39 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2020)
FIGURE 40 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2021 & 2028)
FIGURE 41 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2020 & 2028)
FIGURE 42 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 43 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 44 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 45 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 48 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 49 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 50 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 52 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 53 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 54 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 55 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 56 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 57 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 58 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 59 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 60 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 61 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 62 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 63 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 64 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 65 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 66 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 67 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 68 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 69 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 70 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 71 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 72 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 73 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 74 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 75 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 76 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
